<p>根據 ICICI Prudential Asset Management Co Ltd 最近向 SEC 提交的 13F 表格，該公司在第三季度將其在安進公司（NASDAQ:AMGN - 免費報告）的持股增加了 35.9%。該基金在此期間購買了 8,529 股後，持有 32,267 股該醫療研究公司的股票。安進約佔 ICICI Prudential Asset Management Co Ltd 投資組合的 1.0%，是其第 23 大持倉。截止最近一個季度末，ICICI Prudential Asset Management Co Ltd 在安進的持股價值為 9,106,000 美元。</p>
<ul>
<li>Ozempic、Mounjaro、Wegovy 或 Zepbound？這個 ETF 包含了它們所有。</li>
</ul>
<p>其他幾家機構投資者也買賣了該公司的股票。Pekin Hardy Strauss Inc.在第三季度購買了安進的新股份，價值約為 204,000 美元。Clear Creek Financial Management LLC 在第三季度將其在安進的股份增加了 19.0%。Clear Creek Financial Management LLC 現在持有 2,438 股該醫療研究公司的股票，價值 688,000 美元，此前在上個季度又購買了 390 股。BNP PARIBAS ASSET MANAGEMENT Holding S.A.在第三季度將其在安進的股份增加了 22.5%。BNP PARIBAS ASSET MANAGEMENT Holding S.A.現在持有 192,706 股該醫療研究公司的股票，價值 53,918,000 美元，此前在上個季度又購買了 35,423 股。Wealth Alliance LLC 在第三季度將其在安進的持倉增加了 4.6%。Wealth Alliance LLC 現在持有 13,412 股該醫療研究公司的股票，價值 3,785,000 美元，此前在此期間又購買了 595 股。最後，King Luther Capital Management Corp 在第三季度將其在安進的股份增加了 0.3%。King Luther Capital Management Corp 現在持有 509,158 股該醫療研究公司的股票，價值 143,684,000 美元，此前在上個季度又購買了 1,653 股。機構投資者持有該公司 76.50% 的股票。</p>
<h2>安進股價下跌 1.1%</h2>
<p>安進股票週五開盤價為 375.50 美元。安進公司 12 個月低點為 261.43 美元，12 個月高點為 385.12 美元。該公司的 50 日移動平均線為 342.07 美元，200 日移動平均線為 315.70 美元。公司的市值為 2024.2 億美元，市盈率為 26.39，市盈增長比率為 3.89，貝塔值為 0.46。公司的債務與股本比率為 5.78，流動比率為 1.14，速動比率為 0.90。</p>
<ul>
<li>三家醫療巨頭剛剛提高了股息——看看誰支付得最多</li>
</ul>
<p>安進（NASDAQ:AMGN - 獲取免費報告）最近於 2 月 3 日（星期二）發佈了其財報。該醫療研究公司報告本季度每股收益為 5.29 美元，超出分析師一致預期的 4.76 美元，超出幅度為 0.53 美元。該公司本季度的收入為 98.7 億美元，而一致預期為 94.6 億美元。安進的淨利潤率為 20.98%，股本回報率為 148.37%。與去年同期相比，該公司本季度的收入增長了 8.6%。在去年同期，該公司每股收益為 5.31 美元。安進已將其 2026 財年的指導目標設定為 21.600-23.000 美元每股收益。研究分析師平均預計安進公司今年將發佈 20.62 美元每股收益。</p>
<h2>安進增加股息</h2>
<p>該公司最近還披露了季度股息，將於 3 月 6 日（星期五）支付。2 月 13 日（星期五）的股東將獲得每股 2.52 美元的股息。這相當於每年 10.08 美元的股息，收益率為 2.7%。除息日期為 2 月 13 日（星期五）。這比安進之前的季度股息 2.38 美元有所增加。安進的股息支付比率（DPR）為 70.84%。</p>
<h2>分析師評級變動</h2>
<ul>
<li>5 家醫療公司值得關注，因為行業輪動正在全面展開</li>
</ul>
<p>幾家研究公司最近對安進進行了評估。高盛集團將安進的目標價從 403.00 美元上調至 415.00 美元，並在 2 月 4 日（星期三）的報告中給予該公司 “買入” 評級。Erste Group Bank 在 12 月 5 日（星期五）的研究報告中將安進的評級從 “持有” 上調至 “買入”。Cantor Fitzgerald 將安進的目標價從 315.00 美元上調至 350.00 美元，並在 2 月 4 日（星期三）的研究報告中給予該公司 “中性” 評級。BMO 資本市場將安進的目標價從 335.00 美元上調至 372.00 美元，並在 12 月 3 日（星期三）的研究報告中給予該股票 “跑贏大盤” 評級。最後，Oppenheimer 將安進的目標價設定為 400.00 美元，並在 1 月 29 日（星期四）的報告中給予該公司 “跑贏大盤” 評級。一位研究分析師對該股票給予了強烈買入評級，十五位分析師給予了買入評級，十位分析師給予了持有評級，兩位分析師給予了賣出評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “適度買入”，平均目標價為 345.16 美元。</p>
<p><strong>獲取我們關於安進的最新股票報告</strong></p>
<h2>關於安進</h2>
<p>（免費報告）</p>
<p>安進公司（NASDAQ: AMGN）是一家成立於 1980 年，總部位於加利福尼亞州千橡市的全球生物技術公司。該公司專注於發現、開發、生產和提供針對嚴重疾病的人類治療藥物。安進的工作集中在源自細胞和分子生物學的生物藥物上，強調將人類遺傳學和蛋白質科學的進展轉化為患者的治療方案。</p>
<p>安進的商業產品組合歷來包括用於腫瘤學、支持性護理、腎臟病、骨骼健康和心血管疾病的生物製劑。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們更看好的股票比安進更好</li>
<li>3 個跡象表明您可能想更換財務顧問</li>
<li>巴菲特、蓋茨和貝索斯悄悄拋售股票——原因在這裏</li>
<li>解鎖：埃隆·馬斯克的下一個大 IPO</li>
<li>我的愛潑斯坦故事</li>
<li>新法律：國會批准數字美元的設立？</li>
</ul>
<p><strong>想知道其他對沖基金持有 AMGN 的情況嗎？</strong> 請訪問 HoldingsChannel.com 獲取 Amgen Inc.（NASDAQ:AMGN - 免費報告）的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Amgen 嗎？</h2>
<p>在你考慮 Amgen 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Amgen 並不在名單上。</p>
<p>雖然 Amgen 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

醫療業 ETF - SPDR

標普全球醫療股指數 ETF - iShares

納斯達克生物科技指數 ETF - iShares Nasdaq

<p>ICICI Prudential Asset Management Co Ltd 在第三季度將其在安進（Amgen Inc.）的持股增加了 35.9%，額外購買了 8,529 股，總持股達到 32,267 股，價值 910 萬美元。其他機構投資者也增加了對安進的投資。該股票開盤價為 375.50 美元，12 個月的價格區間為 261.43 美元至 385.12 美元。安進最近報告了強勁的收益，超出預期，並宣佈將每股股息提高至 2.52 美元，收益率為 2.7%</p>

<p>ICICI Prudential Asset Management Co Ltd increased its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 35.9% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 32,267 shares of the medical research company's stock after purchasing an additional 8,529 shares during the period. Amgen makes up about 1.0% of ICICI Prudential Asset Management Co Ltd's investment portfolio, making the stock its 23rd largest position. ICICI Prudential Asset Management Co Ltd's holdings in Amgen were worth $9,106,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>根據 ICICI Prudential Asset Management Co Ltd 最近向 SEC 提交的 13F 表格，該公司在第三季度將其在安進公司（NASDAQ:AMGN - 免費報告）的持股增加了 35.9%。該基金在此期間購買了 8,529 股後，持有 32,267 股該醫療研究公司的股票。安進約佔 ICICI Prudential Asset Management Co Ltd 投資組合的 1.0%，是其第 23 大持倉。截止最近一個季度末，ICICI Prudential Asset Management Co Ltd 在安進的持股價值為 9,106,000 美元。</p>
</div><ul>
<li>Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All</li>
</ul>
<div class="lb-trans"><ul>
<li>Ozempic、Mounjaro、Wegovy 或 Zepbound？這個 ETF 包含了它們所有。</li>
</ul>
</div><p>Several other institutional investors have also bought and sold shares of the business. Pekin Hardy Strauss Inc. purchased a new stake in shares of Amgen during the 3rd quarter valued at about $204,000. Clear Creek Financial Management LLC increased its stake in Amgen by 19.0% during the third quarter. Clear Creek Financial Management LLC now owns 2,438 shares of the medical research company's stock worth $688,000 after acquiring an additional 390 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its stake in Amgen by 22.5% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 192,706 shares of the medical research company's stock worth $53,918,000 after acquiring an additional 35,423 shares during the last quarter. Wealth Alliance LLC raised its position in Amgen by 4.6% during the third quarter. Wealth Alliance LLC now owns 13,412 shares of the medical research company's stock valued at $3,785,000 after purchasing an additional 595 shares during the period. Finally, King Luther Capital Management Corp lifted its stake in shares of Amgen by 0.3% in the 3rd quarter. King Luther Capital Management Corp now owns 509,158 shares of the medical research company's stock valued at $143,684,000 after purchasing an additional 1,653 shares during the last quarter. Institutional investors own 76.50% of the company's stock.</p>
<div class="lb-trans"><p>其他幾家機構投資者也買賣了該公司的股票。Pekin Hardy Strauss Inc.在第三季度購買了安進的新股份，價值約為 204,000 美元。Clear Creek Financial Management LLC 在第三季度將其在安進的股份增加了 19.0%。Clear Creek Financial Management LLC 現在持有 2,438 股該醫療研究公司的股票，價值 688,000 美元，此前在上個季度又購買了 390 股。BNP PARIBAS ASSET MANAGEMENT Holding S.A.在第三季度將其在安進的股份增加了 22.5%。BNP PARIBAS ASSET MANAGEMENT Holding S.A.現在持有 192,706 股該醫療研究公司的股票，價值 53,918,000 美元，此前在上個季度又購買了 35,423 股。Wealth Alliance LLC 在第三季度將其在安進的持倉增加了 4.6%。Wealth Alliance LLC 現在持有 13,412 股該醫療研究公司的股票，價值 3,785,000 美元，此前在此期間又購買了 595 股。最後，King Luther Capital Management Corp 在第三季度將其在安進的股份增加了 0.3%。King Luther Capital Management Corp 現在持有 509,158 股該醫療研究公司的股票，價值 143,684,000 美元，此前在上個季度又購買了 1,653 股。機構投資者持有該公司 76.50% 的股票。</p>
</div><h2>Amgen Trading Down 1.1%</h2>
<div class="lb-trans"><h2>安進股價下跌 1.1%</h2>
</div><p>AMGN stock opened at $375.50 on Friday. Amgen Inc. has a 12 month low of $261.43 and a 12 month high of $385.12. The firm's 50-day moving average is $342.07 and its 200 day moving average is $315.70. The company has a market capitalization of $202.42 billion, a PE ratio of 26.39, a P/E/G ratio of 3.89 and a beta of 0.46. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90.</p>
<div class="lb-trans"><p>安進股票週五開盤價為 375.50 美元。安進公司 12 個月低點為 261.43 美元，12 個月高點為 385.12 美元。該公司的 50 日移動平均線為 342.07 美元，200 日移動平均線為 315.70 美元。公司的市值為 2024.2 億美元，市盈率為 26.39，市盈增長比率為 3.89，貝塔值為 0.46。公司的債務與股本比率為 5.78，流動比率為 1.14，速動比率為 0.90。</p>
</div><ul>
<li>3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most</li>
</ul>
<div class="lb-trans"><ul>
<li>三家醫療巨頭剛剛提高了股息——看看誰支付得最多</li>
</ul>
</div><p>Amgen (NASDAQ:AMGN - Get Free Report) last issued its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping analysts' consensus estimates of $4.76 by $0.53. The business had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The company's revenue for the quarter was up 8.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, research analysts anticipate that Amgen Inc. will post 20.62 EPS for the current year.</p>
<div class="lb-trans"><p>安進（NASDAQ:AMGN - 獲取免費報告）最近於 2 月 3 日（星期二）發佈了其財報。該醫療研究公司報告本季度每股收益為 5.29 美元，超出分析師一致預期的 4.76 美元，超出幅度為 0.53 美元。該公司本季度的收入為 98.7 億美元，而一致預期為 94.6 億美元。安進的淨利潤率為 20.98%，股本回報率為 148.37%。與去年同期相比，該公司本季度的收入增長了 8.6%。在去年同期，該公司每股收益為 5.31 美元。安進已將其 2026 財年的指導目標設定為 21.600-23.000 美元每股收益。研究分析師平均預計安進公司今年將發佈 20.62 美元每股收益。</p>
</div><h2>Amgen Increases Dividend</h2>
<div class="lb-trans"><h2>安進增加股息</h2>
</div><p>The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be issued a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a yield of 2.7%. The ex-dividend date is Friday, February 13th. This is an increase from Amgen's previous quarterly dividend of $2.38. Amgen's dividend payout ratio (DPR) is 70.84%.</p>
<div class="lb-trans"><p>該公司最近還披露了季度股息，將於 3 月 6 日（星期五）支付。2 月 13 日（星期五）的股東將獲得每股 2.52 美元的股息。這相當於每年 10.08 美元的股息，收益率為 2.7%。除息日期為 2 月 13 日（星期五）。這比安進之前的季度股息 2.38 美元有所增加。安進的股息支付比率（DPR）為 70.84%。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><ul>
<li>5 Healthcare Names to Watch as Sector Rotation Is in Full Swing</li>
</ul>
<div class="lb-trans"><ul>
<li>5 家醫療公司值得關注，因為行業輪動正在全面展開</li>
</ul>
</div><p>Several research firms recently weighed in on AMGN. The Goldman Sachs Group increased their price target on Amgen from $403.00 to $415.00 and gave the company a &#34;buy&#34; rating in a report on Wednesday, February 4th. Erste Group Bank upgraded shares of Amgen from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Friday, December 5th. Cantor Fitzgerald increased their target price on shares of Amgen from $315.00 to $350.00 and gave the company a &#34;neutral&#34; rating in a research note on Wednesday, February 4th. BMO Capital Markets lifted their price target on shares of Amgen from $335.00 to $372.00 and gave the stock an &#34;outperform&#34; rating in a research note on Wednesday, December 3rd. Finally, Oppenheimer set a $400.00 price target on shares of Amgen and gave the company an &#34;outperform&#34; rating in a report on Thursday, January 29th. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, ten have assigned a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of &#34;Moderate Buy&#34; and an average price target of $345.16.</p>
<div class="lb-trans"><p>幾家研究公司最近對安進進行了評估。高盛集團將安進的目標價從 403.00 美元上調至 415.00 美元，並在 2 月 4 日（星期三）的報告中給予該公司 “買入” 評級。Erste Group Bank 在 12 月 5 日（星期五）的研究報告中將安進的評級從 “持有” 上調至 “買入”。Cantor Fitzgerald 將安進的目標價從 315.00 美元上調至 350.00 美元，並在 2 月 4 日（星期三）的研究報告中給予該公司 “中性” 評級。BMO 資本市場將安進的目標價從 335.00 美元上調至 372.00 美元，並在 12 月 3 日（星期三）的研究報告中給予該股票 “跑贏大盤” 評級。最後，Oppenheimer 將安進的目標價設定為 400.00 美元，並在 1 月 29 日（星期四）的報告中給予該公司 “跑贏大盤” 評級。一位研究分析師對該股票給予了強烈買入評級，十五位分析師給予了買入評級，十位分析師給予了持有評級，兩位分析師給予了賣出評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “適度買入”，平均目標價為 345.16 美元。</p>
</div><p><strong>Get Our Latest Stock Report on Amgen</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於安進的最新股票報告</strong></p>
</div><h2>About Amgen</h2>
<div class="lb-trans"><h2>關於安進</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.</p>
<div class="lb-trans"><p>安進公司（NASDAQ: AMGN）是一家成立於 1980 年，總部位於加利福尼亞州千橡市的全球生物技術公司。該公司專注於發現、開發、生產和提供針對嚴重疾病的人類治療藥物。安進的工作集中在源自細胞和分子生物學的生物藥物上，強調將人類遺傳學和蛋白質科學的進展轉化為患者的治療方案。</p>
</div><p>Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.</p>
<div class="lb-trans"><p>安進的商業產品組合歷來包括用於腫瘤學、支持性護理、腎臟病、骨骼健康和心血管疾病的生物製劑。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Amgen</li>
<li>3 Signs You May Want to Switch Financial Advisors</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
<li>Unlocked: Elon Musk’s Next Big IPO</li>
<li>My Epstein Story</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票比安進更好</li>
<li>3 個跡象表明您可能想更換財務顧問</li>
<li>巴菲特、蓋茨和貝索斯悄悄拋售股票——原因在這裏</li>
<li>解鎖：埃隆·馬斯克的下一個大 IPO</li>
<li>我的愛潑斯坦故事</li>
<li>新法律：國會批准數字美元的設立？</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding AMGN?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).</p>
<div class="lb-trans"><p><strong>想知道其他對沖基金持有 AMGN 的情況嗎？</strong> 請訪問 HoldingsChannel.com 獲取 Amgen Inc.（NASDAQ:AMGN - 免費報告）的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=AMGN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Amgen Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Amgen 嗎？</h2>
</div><p>Before you consider Amgen, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Amgen 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Amgen 並不在名單上。</p>
</div><p>While Amgen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Amgen 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

ICICI Prudential Asset Management Co Ltd Purchases 8,529 Shares of Amgen Inc. $AMGN

Market Beat

Affiliated Managers

動態生物技術與基因組 ETF - Invesco

安進

基因改革 ETF - ARK

Invesco Nasdaq Biotechnology ETF

2 倍做多納斯達克生物技術 ETF - ProShares

美國制藥 ETF - iShares

醫藥突破 ETF - ALPS

醫療業 ETF - Vanguard

生物科技 ETF - VanEck Vectors

紐交所高增長板生物技術指數 ETF - First Trust

標普生物技術 ETF - SPDR

ICICI Prudential 資產管理有限公司購入了 8,529 股安進公司（Amgen Inc.）的股票